Open AccessProspective Analysis of the Impact of 68Ga-DOTATOC Positron Emission Tomography–Computerized Axial Tomography on Management of Pancreatic and Small Bowel Neuroendocrine Tumors
Author(s) -
Silvia N Ghobrial,
Yusuf Menda,
Gideon Zamba,
Sarah L. Mott,
Kristin Gaimari-Varner,
David Dick,
Joseph S. Dillon,
James R. Howe,
Michael M. Graham,
John Sunderland,
Andrew M. Bellizzi,
Thomas M. O’Dorisio,
M. Sue O’Dorisio
Publication year - 2020
Publication title -
pancreas
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.061
H-Index - 104
eISSN - 1536-4828
pISSN - 0885-3177
DOI - 10.1097/mpa.0000000000001625
Subject(s) - medicine , neuroendocrine tumors , adverse effect , octreotide , positron emission tomography , radiology , abdominal pain , radiation therapy , nausea , lanreotide , somatostatin receptor , somatostatin , growth hormone , acromegaly , hormone
A prospective clinical trial evaluated the effect of Ga-DOTATOC positron emission tomography-computerized axial tomography (PET-CT) on change in management of patients with lung, pancreatic, and small bowel neuroendocrine tumors. The primary eligibility criterion was a histologically proven tumor with positive somatostatin receptor subtype 2A immunohistochemistry. The primary and secondary end points were change in patient management and safety.